Literature DB >> 29273889

Tumor necrosis factor receptor-associated factor 6 is required to inhibit foreign body giant cell formation and activate osteoclasts under inflammatory and infectious conditions.

Akihito Oya1, Eri Katsuyama1, Mayu Morita2, Yuiko Sato1,3, Tami Kobayashi1,4, Kana Miyamoto1, Toru Nishiwaki1, Atsushi Funayama1, Yoshinari Fujita1, Takashi Kobayashi5, Morio Matsumoto1, Masaya Nakamura1, Arihiko Kanaji6, Takeshi Miyamoto7,8.   

Abstract

Osteoclasts and foreign body giant cells (FBGCs) are derived from common progenitors and share properties such as multi-nucleation capacity induced by cell-cell fusion; however, mechanisms underlying lineage determination between these cells remain unclear. Here we show that, under inflammatory conditions, osteoclasts are stimulated in a manner similar to M1 macrophages, while formation of FBGCs, which exhibit M2-like phenotypes, is inhibited in a manner similar to that seen in M1/M2 macrophage polarization. FBGC/osteoclast polarization was inhibited by conditional knockout of tumor necrosis factor receptor associated factor 6 (Traf6) in adults in vivo and in vitro. Traf6-null mice were previously reported to die soon after birth, but we found that Traf6 deletion in adults did not cause lethality but rather inhibited osteoclast activation and prevented FBGC inhibition under inflammatory conditions. Accordingly, basal osteoclastogenesis was significantly inhibited by Traf6 deletion in vivo and in vitro and accompanied by increased bone mass. Lipopolysaccharide-induced osteoclast formation and osteolysis were significantly inhibited in Traf6 conditional knockout mice. Our results suggest that Traf6 plays a crucial role in regulating M1 osteoclast and M2 FBGC polarization and is a potential therapeutic target in blocking FBGC inhibition, antagonizing osteolysis in inflammatory conditions, and increasing bone mass without adverse effects in adults.

Entities:  

Keywords:  Adult; Foreign body giant cells; Foreign body reaction; Osteoclasts; Tumor necrosis factor receptor associated factor 6

Mesh:

Substances:

Year:  2017        PMID: 29273889     DOI: 10.1007/s00774-017-0890-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  43 in total

Review 1.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

2.  Foreign-body giant cells and polyurethane biostability: in vivo correlation of cell adhesion and surface cracking.

Authors:  Q Zhao; N Topham; J M Anderson; A Hiltner; G Lodoen; C R Payet
Journal:  J Biomed Mater Res       Date:  1991-02

Review 3.  Macrophage polarization comes of age.

Authors:  Alberto Mantovani; Antonio Sica; Massimo Locati
Journal:  Immunity       Date:  2005-10       Impact factor: 31.745

4.  Osteoclast stimulatory transmembrane protein and dendritic cell–specific transmembrane protein cooperatively modulate cell–cell fusion to form osteoclasts and foreign body giant cells.

Authors:  Hiroya Miyamoto; Takayuki Suzuki; Yoshiteru Miyauchi; Ryotaro Iwasaki; Tami Kobayashi; Yuiko Sato; Kana Miyamoto; Hiroko Hoshi; Kazuaki Hashimoto; Shigeyuki Yoshida; Wu Hao; Tomoaki Mori; Hiroya Kanagawa; Eri Katsuyama; Atsuhiro Fujie; Hideo Morioka; Morio Matsumoto; Kazuhiro Chiba; Motohiro Takeya; Yoshiaki Toyama; Takeshi Miyamoto
Journal:  J Bone Miner Res       Date:  2012-06       Impact factor: 6.741

5.  Dependence of self-tolerance on TRAF6-directed development of thymic stroma.

Authors:  Taishin Akiyama; Shiori Maeda; Sayaka Yamane; Kaori Ogino; Michiyuki Kasai; Fumiko Kajiura; Mitsuru Matsumoto; Jun-ichiro Inoue
Journal:  Science       Date:  2005-02-10       Impact factor: 47.728

6.  v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation.

Authors:  Seoung-Hoon Lee; Jaerang Rho; Daewon Jeong; Jai-Yoon Sul; Taesoo Kim; Nacksung Kim; Ju-Seob Kang; Takeshi Miyamoto; Toshio Suda; Sun-Kyeong Lee; Robert J Pignolo; Boguslawa Koczon-Jaremko; Joseph Lorenzo; Yongwon Choi
Journal:  Nat Med       Date:  2006-11-26       Impact factor: 53.440

7.  Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling.

Authors:  Jin Gohda; Takayuki Matsumura; Jun-ichiro Inoue
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

8.  TRAF6 is essential for maintenance of regulatory T cells that suppress Th2 type autoimmunity.

Authors:  Go Muto; Hitoshi Kotani; Taisuke Kondo; Rimpei Morita; Sanae Tsuruta; Takashi Kobayashi; Hervé Luche; Hans Joerg Fehling; Matthew Walsh; Yongwon Choi; Akihiko Yoshimura
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

9.  CD44 occupancy prevents macrophage multinucleation.

Authors:  H Sterling; C Saginario; A Vignery
Journal:  J Cell Biol       Date:  1998-11-02       Impact factor: 10.539

10.  Modulation of osteoclastogenesis with macrophage M1- and M2-inducing stimuli.

Authors:  Sujeeve Jeganathan; Cara Fiorino; Urja Naik; He Song Sun; Rene E Harrison
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

View more
  3 in total

1.  Factors influencing multinucleated giant cell formation in vitro.

Authors:  Kevin L Trout; Andrij Holian
Journal:  Immunobiology       Date:  2019-08-10       Impact factor: 3.144

Review 2.  Learning from Monocyte-Macrophage Fusion and Multinucleation: Potential Therapeutic Targets for Osteoporosis and Rheumatoid Arthritis.

Authors:  Laura Gambari; Francesco Grassi; Livia Roseti; Brunella Grigolo; Giovanna Desando
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

3.  Smoking cessation increases levels of osteocalcin and uncarboxylated osteocalcin in human sera.

Authors:  Yasuhiro Kiyota; Hiroyasu Muramatsu; Yuiko Sato; Tami Kobayashi; Kana Miyamoto; Takuji Iwamoto; Morio Matsumoto; Masaya Nakamura; Hiroki Tateno; Kazuki Sato; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2020-10-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.